Integral Health Asset Management, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Integral Health Asset Management, LLC reported 63 stock positions worth $849.4 million. Its top holding was Insmed (INSM) at 12.5% of the portfolio, followed by Tenet Healthcare (THC, 10.4%) and Boston Scientific (BSX, 5.4%). Compared with Q2 2024, it opened 29 new positions, sold out of 35, added to 13 and reduced 14. The biggest buy was a new position in Inspire Medical Systems (INSP) and the biggest sale an exit from Elevance Health (ELV).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001773206
- Portfolio Value
- $849.4M (Q3 2024)
- SEC Filing
- 0001172661-24-004870 ↗ filed Nov 14, 2024
Holdings Value
Holdings 63 stocks · $849.4M
| INSM Insmed Inc. | 12.46% | 1,450,000 | $105.8M | Reduce -6.5% |
| THC Tenet Healthcare Corp. | 10.37% | 530,000 | $88.1M | Add +6.0% |
| BSX Boston Scientific Corp. | 5.43% | 550,000 | $46.1M | Reduce -15.4% |
| CYTK Cytokinetics Inc. | 4.66% | 750,000 | $39.6M | Reduce -25.0% |
| LBPH Longboard Pharmaceuticals Inc. | 4.12% | 1,050,000 | $35.0M | Reduce -4.5% |
| INSP Inspire Medical Systems Inc. | 3.98% | 160,000 | $33.8M | New |
| MDT Medtronic PLC | 3.18% | 300,000 | $27.0M | New |
| BPMC Blueprint Medicines Corp. | 3.16% | 290,000 | $26.8M | Reduce -14.7% |
| EHC Encompass Health Corp. | 3.13% | 275,000 | $26.6M | Reduce -8.3% |
| NVS Novartis AG-Sponsored ADR | 2.71% | 200,000 | $23.0M | Reduce -33.3% |
| ACLX Arcellx Inc. | 2.70% | 275,000 | $23.0M | No change |
| MRK Merck & Co. Inc. | 2.67% | 200,000 | $22.7M | Reduce -14.9% |
| VERA Vera Therapeutics Inc. | 2.60% | 500,000 | $22.1M | No change |
| DGX Quest Diagnostics Inc. | 2.19% | 120,000 | $18.6M | Add +20.0% |
| NARI Inari Medical Inc. | 1.94% | 400,000 | $16.5M | No change |
| RVMD Revolution Medicines Inc. | 1.87% | 350,000 | $15.9M | Add +7.7% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.80% | 300,000 | $15.3M | Reduce -25.0% |
| RGNX Regenxbio Inc. | 1.57% | 1,275,000 | $13.4M | Add +34.2% |
| TARS Tarsus Pharmaceuticals Inc. | 1.45% | 375,000 | $12.3M | Reduce -36.4% |
| COO The Cooper Cos Inc. | 1.43% | 110,000 | $12.1M | New |
| KROS Keros Therapeutics Inc. | 1.37% | 200,000 | $11.6M | Add +135.3% |
| MLTX Moonlake Immunotherapeutics | 1.31% | 220,000 | $11.1M | No change |
| FMS Fresenius Medical Care-ADR | 1.13% | 450,000 | $9.6M | New |
| BRKR Bruker Corp. | 1.10% | 135,000 | $9.3M | Add +3.9% |
| BMY Bristol-Myers Squibb Co. | 1.07% | 175,000 | $9.1M | New |
| LLY Eli Lilly & Co. | 1.04% | 10,000 | $8.9M | No change |
| DXCM Dexcom Inc. | 0.95% | 120,000 | $8.0M | New |
| CPRX Catalyst Pharmaceuticals Inc. | 0.94% | 400,000 | $8.0M | Add +45.5% |
| SANA Sana Biotechnology Inc. | 0.88% | 1,800,000 | $7.5M | Add +50.0% |
| TFX Teleflex Inc. | 0.87% | 30,000 | $7.4M | Reduce -33.3% |
| BTSG Brightspring Health Services | 0.86% | 500,000 | $7.3M | New |
| CRSP Crispr Therapeutics AG | 0.83% | 150,000 | $7.0M | No change |
| ALNY Alnylam Pharmaceuticals Inc. | 0.81% | 25,000 | $6.9M | New |
| APLT Applied Therapeutics Inc. | 0.80% | 800,000 | $6.8M | New |
| JSPR Jasper Therapeutics Inc. | 0.78% | 350,000 | $6.6M | New |
| TNDM Tandem Diabetes Care Inc. | 0.75% | 150,000 | $6.4M | New |
| BNTX Biontech SE-ADR | 0.70% | 50,000 | $5.9M | New |
| QDEL Quidelortho Corp. | 0.67% | 125,000 | $5.7M | Reduce -16.7% |
| VRDN Viridian Therapeutics Inc. | 0.67% | 250,000 | $5.7M | New |
| EVH Evolent Health Inc. Class A | 0.67% | 200,000 | $5.7M | New |
| EXAS Exact Sciences Corp. | 0.64% | 80,000 | $5.4M | New |
| IQV Iqvia Holdings Inc. | 0.56% | 20,000 | $4.7M | New |
| TNYA Tenaya Therapeutics Inc. | 0.54% | 2,375,000 | $4.6M | Add +2.1% |
| TWST Twist Bioscience Corp. | 0.53% | 100,000 | $4.5M | New |
| NRIX Nurix Therapeutics Inc. | 0.53% | 200,000 | $4.5M | Add +33.3% |
| MLYS Mineralys Therapeutics Inc. | 0.51% | 356,000 | $4.3M | New |
| MREO Mereo Biopharma Group PL-ADR | 0.48% | 1,000,000 | $4.1M | Reduce -43.7% |
| RVTY Revvity Inc. | 0.45% | 30,000 | $3.8M | New |
| ETNB 89BIO Inc. | 0.44% | 500,000 | $3.7M | Add +11.1% |
| MYGN Myriad Genetics Inc. | 0.40% | 125,000 | $3.4M | New |
| FATE Fate Therapeutics Inc. | 0.40% | 975,000 | $3.4M | Add +14.7% |
| PLRX Pliant Therapeutics Inc. | 0.40% | 300,000 | $3.4M | New |
| NGNE Neurogene Inc. | 0.35% | 70,000 | $2.9M | No change |
| TERN Terns Pharmaceuticals Inc. | 0.29% | 300,000 | $2.5M | New |
| SRRK Scholar Rock Holding Corp. | 0.26% | 275,000 | $2.2M | Reduce -31.3% |
| CABA Cabaletta Bio Inc. | 0.25% | 450,000 | $2.1M | Add +5.9% |
| NTLA Intellia Therapeutics Inc. | 0.24% | 100,000 | $2.1M | New |
| QURE Uniqure NV | 0.23% | 400,000 | $2.0M | New |
| GEHC GE Healthcare Technology | 0.22% | 20,000 | $1.9M | New |
| STAA Staar Surgical Co. | 0.22% | 50,000 | $1.9M | New |
| TNGX Tango Therapeutics Inc. | 0.18% | 200,000 | $1.5M | New |
| RZLT Rezolute Inc. | 0.14% | 250,000 | $1.2M | New |
| KYTX Kyverna Therapeutics Inc. | 0.12% | 200,000 | $978K | New |
Options reported separately and not counted above: VKTX calls ($15.8M), EWTX calls ($13.3M), CLDX calls ($10.2M).
Portfolio Sells Q2 2024 → Q3 2024
| ELV Elevance Health Inc. | Sold out | 0.00% | −4.31 |
| HUM Humana Inc. | Sold out | 0.00% | −2.79 |
| UHS Universal Health Services-B | Sold out | 0.00% | −2.39 |
| BDX Becton Dickinson and Co. | Sold out | 0.00% | −1.74 |
| CI The Cigna Group | Sold out | 0.00% | −1.65 |
| KRYS Krystal Biotech Inc. | Sold out | 0.00% | −1.55 |
| ICLR Icon PLC | Sold out | 0.00% | −1.40 |
| EW Edwards Lifesciences Corp. | Sold out | 0.00% | −1.38 |
| TMO Thermo Fisher Scientific Inc. | Sold out | 0.00% | −1.38 |
| VKTX Viking Therapeutics Inc. | Sold out | 0.00% | −1.32 |
| AMGN Amgen Inc. | Sold out | 0.00% | −1.24 |
| IONS Ionis Pharmaceuticals Inc. | Sold out | 0.00% | −1.19 |
| MCK McKesson Corp. | Sold out | 0.00% | −1.16 |
| ITCI Intra-Cellular Therapies Inc. | Sold out | 0.00% | −0.99 |
| SNY Sanofi-ADR | Sold out | 0.00% | −0.97 |
| NBIX Neurocrine Biosciences Inc. | Sold out | 0.00% | −0.96 |
| GMED Globus Medical Inc. Class A | Sold out | 0.00% | −0.85 |
| OSCR Oscar Health Inc. Class A | Sold out | 0.00% | −0.79 |
| RGEN Repligen Corp. | Sold out | 0.00% | −0.75 |
| DNLI Denali Therapeutics Inc. | Sold out | 0.00% | −0.75 |
| CYTK Cytokinetics Inc. | Reduce -25.0% | 4.66% | −0.73 |
| ELAN Elanco Animal Health Inc. | Sold out | 0.00% | −0.65 |
| MRUS Merus NV | Sold out | 0.00% | −0.59 |
| PODD Insulet Corp. | Sold out | 0.00% | −0.50 |
| BPMC Blueprint Medicines Corp. | Reduce -14.7% | 3.16% | −0.49 |
| RLAY Relay Therapeutics Inc. | Sold out | 0.00% | −0.49 |
| SGRY Surgery Partners Inc. | Sold out | 0.00% | −0.47 |
| NVS Novartis AG-Sponsored ADR | Reduce -33.3% | 2.71% | −0.47 |
| CRBP Corbus Pharmaceuticals Holdi | Sold out | 0.00% | −0.45 |
| ISRG Intuitive Surgical Inc. | Sold out | 0.00% | −0.44 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −0.42 |
| HOLX Hologic Inc. | Sold out | 0.00% | −0.37 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −0.35 |
| EDIT Editas Medicine Inc. | Sold out | 0.00% | −0.31 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −0.31 |
| SYRE Spyre Therapeutics Inc. | Sold out | 0.00% | −0.23 |
| MRK Merck & Co. Inc. | Reduce -14.9% | 2.67% | −0.22 |
| KURA Kura Oncology Inc. | Sold out | 0.00% | −0.20 |
| MREO Mereo Biopharma Group PL-ADR | Reduce -43.7% | 0.48% | −0.15 |
| TARS Tarsus Pharmaceuticals Inc. | Reduce -36.4% | 1.45% | −0.14 |
| RVNC Revance Therapeutics Inc. | Sold out | 0.00% | −0.13 |
| SRRK Scholar Rock Holding Corp. | Reduce -31.3% | 0.26% | −0.07 |
| TFX Teleflex Inc. | Reduce -33.3% | 0.87% | −0.07 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -25.0% | 1.80% | +0.02 |
| QDEL Quidelortho Corp. | Reduce -16.7% | 0.67% | +0.18 |
| BSX Boston Scientific Corp. | Reduce -15.4% | 5.43% | +0.44 |
| EHC Encompass Health Corp. | Reduce -8.3% | 3.13% | +0.57 |
| LBPH Longboard Pharmaceuticals Inc. | Reduce -4.5% | 4.12% | +1.16 |
| INSM Insmed Inc. | Reduce -6.5% | 12.46% | +2.13 |
Portfolio Buys Q2 2024 → Q3 2024
| INSP Inspire Medical Systems Inc. | New | 3.98% | +3.98 |
| THC Tenet Healthcare Corp. | Add +6.0% | 10.37% | +3.75 |
| MDT Medtronic PLC | New | 3.18% | +3.18 |
| COO The Cooper Cos Inc. | New | 1.43% | +1.43 |
| FMS Fresenius Medical Care-ADR | New | 1.13% | +1.13 |
| BMY Bristol-Myers Squibb Co. | New | 1.07% | +1.07 |
| KROS Keros Therapeutics Inc. | Add +135.3% | 1.37% | +0.98 |
| DXCM Dexcom Inc. | New | 0.95% | +0.95 |
| BTSG Brightspring Health Services | New | 0.86% | +0.86 |
| DGX Quest Diagnostics Inc. | Add +20.0% | 2.19% | +0.83 |
| ALNY Alnylam Pharmaceuticals Inc. | New | 0.81% | +0.81 |
| APLT Applied Therapeutics Inc. | New | 0.80% | +0.80 |
| JSPR Jasper Therapeutics Inc. | New | 0.78% | +0.78 |
| TNDM Tandem Diabetes Care Inc. | New | 0.75% | +0.75 |
| BNTX Biontech SE-ADR | New | 0.70% | +0.70 |
| VRDN Viridian Therapeutics Inc. | New | 0.67% | +0.67 |
| EVH Evolent Health Inc. Class A | New | 0.67% | +0.67 |
| EXAS Exact Sciences Corp. | New | 0.64% | +0.64 |
| RVMD Revolution Medicines Inc. | Add +7.7% | 1.87% | +0.61 |
| IQV Iqvia Holdings Inc. | New | 0.56% | +0.56 |
| TWST Twist Bioscience Corp. | New | 0.53% | +0.53 |
| CPRX Catalyst Pharmaceuticals Inc. | Add +45.5% | 0.94% | +0.51 |
| MLYS Mineralys Therapeutics Inc. | New | 0.51% | +0.51 |
| RGNX Regenxbio Inc. | Add +34.2% | 1.57% | +0.47 |
| RVTY Revvity Inc. | New | 0.45% | +0.45 |
| MYGN Myriad Genetics Inc. | New | 0.40% | +0.40 |
| PLRX Pliant Therapeutics Inc. | New | 0.40% | +0.40 |
| TERN Terns Pharmaceuticals Inc. | New | 0.29% | +0.29 |
| BRKR Bruker Corp. | Add +3.9% | 1.10% | +0.27 |
| NTLA Intellia Therapeutics Inc. | New | 0.24% | +0.24 |
| QURE Uniqure NV | New | 0.23% | +0.23 |
| SANA Sana Biotechnology Inc. | Add +50.0% | 0.88% | +0.23 |
| GEHC GE Healthcare Technology | New | 0.22% | +0.22 |
| STAA Staar Surgical Co. | New | 0.22% | +0.22 |
| NRIX Nurix Therapeutics Inc. | Add +33.3% | 0.53% | +0.22 |
| TNGX Tango Therapeutics Inc. | New | 0.18% | +0.18 |
| RZLT Rezolute Inc. | New | 0.14% | +0.14 |
| FATE Fate Therapeutics Inc. | Add +14.7% | 0.40% | +0.12 |
| KYTX Kyverna Therapeutics Inc. | New | 0.12% | +0.12 |
| ETNB 89BIO Inc. | Add +11.1% | 0.44% | +0.08 |
| CABA Cabaletta Bio Inc. | Add +5.9% | 0.25% | −0.07 |
| TNYA Tenaya Therapeutics Inc. | Add +2.1% | 0.54% | −0.18 |
Options Activity Q2 2024 → Q3 2024
| IONS Ionis Pharmaceuticals Inc. | call | Sold out | 500,000 | $23.8Mbefore exit |
| EWTX Edgewise Therapeutics Inc. | call | New | 500,000 | $13.3M |
| TARS Tarsus Pharmaceuticals Inc. | put | Sold out | 400,000 | $10.9Mbefore exit |
| CLDX Celldex Therapeutics Inc. | call | New | 300,000 | $10.2M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 89 | $2.4B | RVMD, INSM, CYTK, CVS, EWTX |
| Q1 2026 | 86 | $1.9B | INSM, RVMD, CYTK, REGN, VERA |
| Q4 2025 | 84 | $2.0B | INSM, RVMD, VERA, CYTK, REGN |
| Q3 2025 | 72 | $1.4B | INSM, CYTK, THC, MLYS, VERA |
| Q2 2025 | 70 | $1.1B | INSM, BSX, THC, EHC, MLYS |
| Q1 2025 | 76 | $902.7M | INSM, BSX, CYTK, THC, MLYS |
| Q4 2024 | 81 | $1.1B | INSM, THC, BSX, VERA, CYTK |
| Q3 2024 | 63 | $849.4M | INSM, THC, BSX, CYTK, LBPH |
| Q2 2024 | 69 | $1.0B | INSM, THC, CYTK, BSX, ELV |
| Q1 2024 | 76 | $1.0B | THC, BSX, VKTX, INSM, CYTK |